DEA telehealth prescribing rule reaches White House review

The DEA has submitted a final controlled-substance telehealth-prescribing rule for White House review, an important procedural step after years of temporary extensions. The rule’s substance, release timing, legal basis, and practical effects on clinicians and patients remain unknown.